{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-000168","form_type":"8-K","ticker":"CBDW","cik":"0001877461","company_name":"1606 CORP.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.448103+00:00","generated_at":"2026-05-28T03:55:13.368124+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"medium","headline":"1606 Corp. applauds Adnexus Biotechnologies' AI-developed malaria drug Trapicolast; LOI terminated but deal progressing","bullets":["1606 Corp. expresses strong support for strategic investment target Adnexus Biotechnologies after Trapicolast announcement.","Trapicolast targets apicoplast and vesicular trafficking in Plasmodium; developed via Sutra™ AI platform analyzing 8M+ compounds.","Adnexus and 1606 Corp. previously signed a LOI that terminated Nov 28, 2024; parties still moving forward to close transaction.","CEO Austen Lambrecht highlights AI-driven innovation for global health challenges."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-000168","json":"https://secwatch.observer/filing/0001477932-25-000168.json","markdown":"https://secwatch.observer/filing/0001477932-25-000168.md","text":"https://secwatch.observer/filing/0001477932-25-000168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877461/000147793225000168/0001477932-25-000168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877461/000147793225000168/onesix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:55:13.368124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}